Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Placebo-controlled Study With an Open Dose Selection Period for Assessing the Safety and Immunogenicity of the Drug "BVRS-GamVac-Combi", a Combined Vector Vaccine for the Prevention of the Middle East Respiratory Syndrome, Lyophilisate for the Preparation of a Solution for Intramuscular Administration, With the Participation of Healthy Volunteers

NCT04128059 is registered in ClinicalTrials.gov with Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation as lead sponsor.

NCT NCT04128059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04128059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Placebo-controlled Study With an Open Dose Selection Period for Assessing the Safety and Immunogenicity of the Drug "BVRS-GamVac-Combi", a Combined Vector Vaccine for the Prevention of the Middle East Respiratory Syndrome, Lyophilisate for the Preparation of a Solution for Intramuscular Administration, With the Participation of Healthy Volunteers
Lead sponsor
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 6, 2019
Completion date
December 31, 2021
Enrollment
268 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mers, mers (middle east respiratory syndrome)